Allos Therapeutics Inc - Current report filing (8-K)
29 Maio 2008 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 29, 2008
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
|
|
|
Westminster, Colorado
|
|
80020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 7 Regulation FD
Item 7.01 Regulation FD Disclosure.
On
May 29, 2008, Allos Therapeutics, Inc. issued a press release
announcing the closing of its previously announced public offering of
12,420,000 shares of newly issued common stock at a public offering price of
$5.64 per share (which includes 1,620,000 shares purchased by the underwriters
pursuant to their exercise in full of their overallotment option). The press release is attached hereto as Exhibit 99.1
and incorporated herein by reference.
In
accordance with General Instruction B.2. of Form 8-K, the information
presented under this Item 7.01 and attached as Exhibit 99.1 shall not
be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such a filing.
Section 9
|
|
Financial
Statements and Exhibits
|
|
|
|
Item 9.01
|
|
Financial
Statements and Exhibits.
|
|
|
|
(d)
|
|
Exhibits.
|
|
|
|
99.1
|
|
Press
Release, dated May 29, 2008, entitled Allos Therapeutics Announces Closing of Public Common Stock Offering;
Underwriters Exercise Overallotment Option to Purchase Additional 1,620,000
Shares.
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 29,
2008
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
Marc
H. Graboyes
|
|
Its:
|
Senior
Vice President, General Counsel and Secretary
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press
Release, dated May 29, 2008, entitled Allos Therapeutics Announces Closing of Public Common Stock Offering;
Underwriters Exercise Overallotment Option to Purchase Additional 1,620,000
Shares.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024